首页 > 最新文献

Drug metabolism and personalized therapy最新文献

英文 中文
Ayurvedic medicines in alleviating the symptoms of SARS-CoV-2 omicron variant in North Indian population: a regional genomic study. 阿育吠陀药物缓解北印度人群严重急性呼吸系统综合征冠状病毒2型奥密克戎变异株症状:一项区域基因组研究。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-04-17 eCollection Date: 2023-09-01 DOI: 10.1515/dmpt-2023-0009
Konduru Rama Chandra Reddy, Chetan Sahni, Royana Singh, Hari Chandana, Rohit Sharma
{"title":"Ayurvedic medicines in alleviating the symptoms of SARS-CoV-2 omicron variant in North Indian population: a regional genomic study.","authors":"Konduru Rama Chandra Reddy, Chetan Sahni, Royana Singh, Hari Chandana, Rohit Sharma","doi":"10.1515/dmpt-2023-0009","DOIUrl":"10.1515/dmpt-2023-0009","url":null,"abstract":"","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 3","pages":"289-291"},"PeriodicalIF":0.0,"publicationDate":"2023-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10281178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Evaluation of the efficacy of topical Terminalia chebula Retz. with vinegar in the treatment of tinea corporis: a non-inferiority randomized controlled trial. 局部使用切布Terminala Retz的疗效评价。食醋治疗体癣:一项非劣效性随机对照试验。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-04-04 eCollection Date: 2023-09-01 DOI: 10.1515/dmpt-2022-0188
Sumayya Tasneem Parapur, Nazim Husain, Mohd Khalid, Saba Abdul Razzaq Mamdapur, Khan Ameer Kauser Khan

Objectives: Unani physicians have suggested a wide range of anti-dermatophytic remedies, although the scientific evidence is scarce. Thus, the efficacy and safety of Terminalia chebula Retz. fruit powder mixed with vinegar was compared with terbinafine hydrochloride 1% cream in the treatment of tinea corporis in order to establish the non-inferiority of test drugs.

Methods: The primary outcome measures were change in the presence or absence of hyphae on KOH mount test, change in pruritus severity assessed on 100 mm VAS and change in physician's global assessment. Secondary outcome measure was change in the dermatology life quality index (DLQI). Hemograms, serum creatinine, serum bilirubin, and random blood sugar levels were measured at the baseline and after treatment to ensure the safety of the interventions.

Results: A per-protocol analysis was done on 40 participants (21 in the test group and 19 in the control group). The observed differences in the primary and secondary outcomes between the test and control groups were greater than the non-inferiority margin, signifying that the test drugs were not inferior.

Conclusions: It may be inferred that the trial drug Terminalia chebula Retz. fruit powder mixed with vinegar is not inferior to terbinafine hydrochloride cream in the treatment of tinea corporis.

目的:尽管科学证据很少,但Unani的医生提出了一系列广泛的抗皮肤病药物。因此,评价了车前子的有效性和安全性。将果粉加醋与1%盐酸特比萘芬乳膏治疗体癣进行比较,以确定试验药物的非劣效性。方法:主要的结果指标是KOH悬置试验中是否存在菌丝的变化、100 mm VAS评估的瘙痒严重程度的变化以及医生的总体评估的变化。次要的结果指标是皮肤科生活质量指数(DLQI)的变化。在基线和治疗后测量血红蛋白、血清肌酐、血清胆红素和随机血糖水平,以确保干预措施的安全性。结果:对40名参与者(试验组21名,对照组19名)进行了按方案分析。试验组和对照组之间观察到的主要和次要结果的差异大于非劣效性界限,这表明试验药物没有劣效性。结论:可以推断出该试验药物为车尾。果粉加醋治疗体癣疗效不亚于盐酸特比萘芬乳膏。
{"title":"Evaluation of the efficacy of topical <i>Terminalia chebula</i> Retz. with vinegar in the treatment of tinea corporis: a non-inferiority randomized controlled trial.","authors":"Sumayya Tasneem Parapur, Nazim Husain, Mohd Khalid, Saba Abdul Razzaq Mamdapur, Khan Ameer Kauser Khan","doi":"10.1515/dmpt-2022-0188","DOIUrl":"10.1515/dmpt-2022-0188","url":null,"abstract":"<p><strong>Objectives: </strong>Unani physicians have suggested a wide range of anti-dermatophytic remedies, although the scientific evidence is scarce. Thus, the efficacy and safety of <i>Terminalia chebula</i> Retz. fruit powder mixed with vinegar was compared with terbinafine hydrochloride 1% cream in the treatment of tinea corporis in order to establish the non-inferiority of test drugs.</p><p><strong>Methods: </strong>The primary outcome measures were change in the presence or absence of hyphae on KOH mount test, change in pruritus severity assessed on 100 mm VAS and change in physician's global assessment. Secondary outcome measure was change in the dermatology life quality index (DLQI). Hemograms, serum creatinine, serum bilirubin, and random blood sugar levels were measured at the baseline and after treatment to ensure the safety of the interventions.</p><p><strong>Results: </strong>A per-protocol analysis was done on 40 participants (21 in the test group and 19 in the control group). The observed differences in the primary and secondary outcomes between the test and control groups were greater than the non-inferiority margin, signifying that the test drugs were not inferior.</p><p><strong>Conclusions: </strong>It may be inferred that the trial drug <i>Terminalia chebula</i> Retz. fruit powder mixed with vinegar is not inferior to terbinafine hydrochloride cream in the treatment of tinea corporis.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 3","pages":"237-245"},"PeriodicalIF":0.0,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10626424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Histomorphological study of hepatic lobules of adult Wistar rats administered with aqueous extracts of leaves of cassia singueana. 决明子叶水提物对成年Wistar大鼠肝小叶的组织形态学研究。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-03-20 DOI: 10.1515/dmpt-2023-0002
Jemila Alley, Adam N Jibril, Sagir M Saleh, Mikail Umar, Mujittapha U Sirajo

Objectives: Cassia singueana is widely used in northern Nigeria as an herb for the treatment of enamors ailments. Nevertheless the toxicity of the herb on liver architecture; the hepatic lobule and body weight is yet to be authenticated.

Methods: A total of 24 male Wistar rats with an average weight of 150 g were randomly placed into four groups. Each group consisted of 6 rats. Group A served as the control group while groups B, C and D were given 150, 300, and 450 mg of Cassia singueana leaves extract respectively for 14 days. The animals were weighed before, during and after the treatment phase subsequently, they were sacrificed and the liver tissues were processed and stained using hematoxylin and eosin (H&E) stain, Masson's and Trichrome Stain, Gordon and Sweet's Stain, and Periodic Acid Schiff (PAS)Stain.

Results: There was no significant change in the animal's body weight of in all the groups when compared to the control group. Our histology result showed that Cassia singueana induced vascular lesion and hepatocytes degeneration putatively though mechanism of cell death (apoptosis and necrosis). It was also found that Cassia singueana has no toxic effect on the reticular fibers of the liver. High dose of Cassia singueana was found to induce the deposition of PAS positive materials in hepatocytes.

Conclusions: The Cassia singueana leaves extract induce hepatocyte degeneration and vascular lesion in the hepatic lobules of the wistar rats, without affecting the animals' body weight.

目的:决明子在尼日利亚北部被广泛用作治疗釉病的草药。然而,草药对肝脏结构的毒性;肝小叶和体重还有待鉴定。方法:取24只平均体重150 g的雄性Wistar大鼠,随机分为4组。每组6只大鼠。A组为对照组,B、C、D组分别给予桂花叶提取物150、300、450 mg,持续14 D。在治疗前、治疗中、治疗后称重,处死动物,处理肝脏组织,采用苏木精伊红(H&E)染色、马松三色染色、戈登和斯威氏染色、周期性酸希夫(PAS)染色。结果:与对照组相比,各组动物体重均无显著变化。组织学结果表明,决明子通过细胞死亡机制(凋亡和坏死)诱导血管病变和肝细胞变性。同时发现决明子对肝脏网状纤维无毒性作用。高剂量决明子可诱导肝细胞PAS阳性物质的沉积。结论:决明子叶提取物可诱导wistar大鼠肝细胞变性和肝小叶血管病变,但不影响动物体重。
{"title":"Histomorphological study of hepatic lobules of adult Wistar rats administered with aqueous extracts of leaves of <i>cassia singueana</i>.","authors":"Jemila Alley,&nbsp;Adam N Jibril,&nbsp;Sagir M Saleh,&nbsp;Mikail Umar,&nbsp;Mujittapha U Sirajo","doi":"10.1515/dmpt-2023-0002","DOIUrl":"https://doi.org/10.1515/dmpt-2023-0002","url":null,"abstract":"<p><strong>Objectives: </strong><i>Cassia singueana</i> is widely used in northern Nigeria as an herb for the treatment of enamors ailments. Nevertheless the toxicity of the herb on liver architecture; the hepatic lobule and body weight is yet to be authenticated.</p><p><strong>Methods: </strong>A total of 24 male Wistar rats with an average weight of 150 g were randomly placed into four groups. Each group consisted of 6 rats. Group A served as the control group while groups B, C and D were given 150, 300, and 450 mg of <i>Cassia singueana</i> leaves extract respectively for 14 days. The animals were weighed before, during and after the treatment phase subsequently, they were sacrificed and the liver tissues were processed and stained using hematoxylin and eosin (H&E) stain, Masson's and Trichrome Stain, Gordon and Sweet's Stain, and Periodic Acid Schiff (PAS)Stain.</p><p><strong>Results: </strong>There was no significant change in the animal's body weight of in all the groups when compared to the control group. Our histology result showed that <i>Cassia singueana</i> induced vascular lesion and hepatocytes degeneration putatively though mechanism of cell death (apoptosis and necrosis). It was also found that <i>Cassia singueana</i> has no toxic effect on the reticular fibers of the liver. High dose of <i>Cassia singueana</i> was found to induce the deposition of PAS positive materials in hepatocytes.</p><p><strong>Conclusions: </strong><i>The Cassia singueana</i> leaves extract induce hepatocyte degeneration and vascular lesion in the hepatic lobules of the wistar rats, without affecting the animals' body weight.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9138650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Exploratory quasi-experimental study of anti-arthritic activity of Ayurvedic polyherbal formulation, Abha Guggulu in osteoarthritis patients. 阿育吠陀多羟基制剂Abha Guggulu对骨关节炎患者抗关节炎活性的探索性准实验研究。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-03-16 eCollection Date: 2023-09-01 DOI: 10.1515/dmpt-2022-0187
Mrinmayee Hedaoo, Trupti Patil-Bhole, Rohit Sharma, Madhavi Mahajan

Objectives: Abha Guggulu (AG) is a traditional Ayurvedic herbal formulation used for treating joint disorders and bone fractures. Individually, the ingredients are known for their promising anti-inflammatory and rejuvenating actions. The present study attempts to explore the anti-arthritic potential of AG through an exploratory clinical trial.

Methods: The study was conducted using a quasi-experimental model. The clinical trial has been registered in Clinical Trials Registry of India (registration number: CTRI/2019/09/021354). Osteoarthritis patients of both genders (n=12, 40-70 years age group), meeting the inclusion/exclusion criteria, were recruited in the single arm study. AG was administered in tablet form in a dose of 1.5 g, twice daily. The WOMAC score was used as a primary outcome measure. The WOMAC scale of patients was recorded on 0th, 15th and 30th days of treatment.

Results: At the end of treatment, there was a significant difference in the scores of the outcome measure. As per WOMAC total score, participants were significantly improved (p=0.002) after consuming the drug for 1 month.

Conclusions: Overall, the data indicates significant improvement of subjects in both scales and objective measures used for assessment purposes. There were no adverse drug reactions reported during the trial. AG may be used as a safe and effective supplement to reduce symptoms of osteoarthritis. The clinical efficacy of the formulation might be mediated through the synergistic blend of herbal bioactive compounds from AG.

目的:Abha Guggulu(AG)是一种传统的阿育吠陀草药配方,用于治疗关节疾病和骨折。就个人而言,这些成分以其有前景的抗炎和恢复活力的作用而闻名。本研究试图通过一项探索性临床试验来探索AG的抗关节炎潜力。方法:采用准实验模型进行研究。该临床试验已在印度临床试验注册中心注册(注册号:CTRI/2019/09/021354)。单臂研究招募了符合纳入/排除标准的两性(n=12,40-70岁年龄组)骨关节炎患者。AG以片剂形式给药,剂量为1.5g,每天两次。WOMAC评分被用作主要的结果测量。在治疗的第0天、第15天和第30天记录患者的WOMAC量表。结果:在治疗结束时,结果测量的得分有显著差异。根据WOMAC总分,参与者在服用药物1个月后显著改善(p=0.002)。结论:总体而言,数据表明受试者在用于评估目的的量表和客观指标方面都有显著改善。试验期间未报告药物不良反应。AG可以作为一种安全有效的补充剂来减轻骨关节炎的症状。该制剂的临床疗效可能通过来自AG的草药生物活性化合物的协同混合物来介导。
{"title":"Exploratory quasi-experimental study of anti-arthritic activity of Ayurvedic polyherbal formulation, Abha Guggulu in osteoarthritis patients.","authors":"Mrinmayee Hedaoo,&nbsp;Trupti Patil-Bhole,&nbsp;Rohit Sharma,&nbsp;Madhavi Mahajan","doi":"10.1515/dmpt-2022-0187","DOIUrl":"10.1515/dmpt-2022-0187","url":null,"abstract":"<p><strong>Objectives: </strong>Abha Guggulu (AG) is a traditional Ayurvedic herbal formulation used for treating joint disorders and bone fractures. Individually, the ingredients are known for their promising anti-inflammatory and rejuvenating actions. The present study attempts to explore the anti-arthritic potential of AG through an exploratory clinical trial.</p><p><strong>Methods: </strong>The study was conducted using a quasi-experimental model. The clinical trial has been registered in Clinical Trials Registry of India (registration number: CTRI/2019/09/021354). Osteoarthritis patients of both genders (n=12, 40-70 years age group), meeting the inclusion/exclusion criteria, were recruited in the single arm study. AG was administered in tablet form in a dose of 1.5 g, twice daily. The WOMAC score was used as a primary outcome measure. The WOMAC scale of patients was recorded on 0th, 15th and 30th days of treatment.</p><p><strong>Results: </strong>At the end of treatment, there was a significant difference in the scores of the outcome measure. As per WOMAC total score, participants were significantly improved (p=0.002) after consuming the drug for 1 month.</p><p><strong>Conclusions: </strong>Overall, the data indicates significant improvement of subjects in both scales and objective measures used for assessment purposes. There were no adverse drug reactions reported during the trial. AG may be used as a safe and effective supplement to reduce symptoms of osteoarthritis. The clinical efficacy of the formulation might be mediated through the synergistic blend of herbal bioactive compounds from AG.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 3","pages":"281-288"},"PeriodicalIF":0.0,"publicationDate":"2023-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10295824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Lack of exposure to pharmacogenomics education among the health care providing students in the West Bank of Palestine. 巴勒斯坦西岸提供医疗保健的学生缺乏药物基因组学教育。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-03-13 eCollection Date: 2023-09-01 DOI: 10.1515/dmpt-2022-0180
Yazun Jarrar, Rami Musleh, Anas Hamdan, Mustafa Ghanim, Malik Alqub, Sara Abudahab

Objectives: Evaluating the knowledge in pharmacogenomics (PGx) is the first step toward the implementation of PGx testing in clinical practice. This survey aimed to evaluate the knowledge of PGx testing among healthcare providing students at the top-ranked university in the West Bank of Palestine.

Methods: First an online questionnaire consisting of 30 questions regarding the demographic, knowledge, and attitude toward pharmacogenomics testing was structured and validated. Then the questionnaire was distributed to 1,000 current students from different fields.

Results: 696 responses was received. The results showed that almost half of the participants (n=355, 51.1%) have never took any courses about PGx during their university training. Only 81 (11.7%) of the students who took the PGx course stated that it helped them understanding how genetic variations affect drug response. The majority of the students were uncertain (n=352, 50.6%) or disagreed (n=143, 20.6%) that the lectures during university education described the effects of genetic variants on drug response. Although most of the students (70-80%) answered that genetic variants can indeed affect the drug's response, only 162 students (23.3%) responded that VKORC1 and CYP2C9 genotypes influence the response to warfarin. In addition, only 94 (13.5%) students were aware that many medicine labels include clinical information about PGx testing provided by the FDA.

Conclusions: It is concluded from the results of this survey that there is a lack of exposure to PGx education associated with poor knowledge of PGx testing among the healthcare providing students in the West Bank of Palestine. It is recommended to include and improve the lectures and courses regarding PGx as this will have a major impact on precision medicine.

目的:评估药物基因组学(PGx)知识是在临床实践中实施PGx测试的第一步。这项调查旨在评估巴勒斯坦西岸顶尖大学医疗保健专业学生对PGx检测的了解。方法:首先,构建并验证了一份由30个问题组成的在线问卷,内容涉及药物基因组学检测的人口统计学、知识和态度。然后将问卷分发给来自不同领域的1000名在校学生。结果:收到696份回复。结果显示,几乎一半的参与者(n=355,51.1%)在大学培训期间从未参加过任何关于PGx的课程。只有81名(11.7%)参加PGx课程的学生表示,这有助于他们理解基因变异如何影响药物反应。大多数学生不确定(n=352,50.6%)或不同意(n=143,20.6%)大学教育期间的讲座描述了基因变异对药物反应的影响。尽管大多数学生(70-80%)回答说基因变异确实会影响药物的反应,但只有162名学生(23.3%)回答说VKORC1和CYP2C9基因型会影响对华法林的反应。此外,只有94名(13.5%)学生知道许多药品标签上包含了美国食品药品监督管理局提供的有关PGx检测的临床信息。建议纳入并改进有关PGx的讲座和课程,因为这将对精准医学产生重大影响。
{"title":"Lack of exposure to pharmacogenomics education among the health care providing students in the West Bank of Palestine.","authors":"Yazun Jarrar,&nbsp;Rami Musleh,&nbsp;Anas Hamdan,&nbsp;Mustafa Ghanim,&nbsp;Malik Alqub,&nbsp;Sara Abudahab","doi":"10.1515/dmpt-2022-0180","DOIUrl":"10.1515/dmpt-2022-0180","url":null,"abstract":"<p><strong>Objectives: </strong>Evaluating the knowledge in pharmacogenomics (PGx) is the first step toward the implementation of PGx testing in clinical practice. This survey aimed to evaluate the knowledge of PGx testing among healthcare providing students at the top-ranked university in the West Bank of Palestine.</p><p><strong>Methods: </strong>First an online questionnaire consisting of 30 questions regarding the demographic, knowledge, and attitude toward pharmacogenomics testing was structured and validated. Then the questionnaire was distributed to 1,000 current students from different fields.</p><p><strong>Results: </strong>696 responses was received. The results showed that almost half of the participants (n=355, 51.1%) have never took any courses about PGx during their university training. Only 81 (11.7%) of the students who took the PGx course stated that it helped them understanding how genetic variations affect drug response. The majority of the students were uncertain (n=352, 50.6%) or disagreed (n=143, 20.6%) that the lectures during university education described the effects of genetic variants on drug response. Although most of the students (70-80%) answered that genetic variants can indeed affect the drug's response, only 162 students (23.3%) responded that <i>VKORC1</i> and <i>CYP2C9</i> genotypes influence the response to warfarin. In addition, only 94 (13.5%) students were aware that many medicine labels include clinical information about PGx testing provided by the FDA.</p><p><strong>Conclusions: </strong>It is concluded from the results of this survey that there is a lack of exposure to PGx education associated with poor knowledge of PGx testing among the healthcare providing students in the West Bank of Palestine. It is recommended to include and improve the lectures and courses regarding PGx as this will have a major impact on precision medicine.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 3","pages":"267-272"},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10626396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
CTH G1208T and MTHFR A1298C polymorphisms are associated with a higher risk of a first myocardial infarction with fatal outcome among women. 在女性中,CTH G1208T和MTHFR A1298C多态性与首次心肌梗死的高风险相关。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-03-01 DOI: 10.1515/dmpt-2022-0119
Elisabet Söderström, Jonas Andersson, Stefan Söderberg, Bethany van Guelpen, Torbjörn K Nilsson, Johan Hultdin

Objectives: Cystathionine-gamma-lyase (CSE) in the transsulfuration pathway generates hydrogen sulfide (H2S), suggested regulating cardiovascular function. The G1208T polymorphism in the CTH gene, rs1021737, has, in addition to MTHFR, been found to increase homocysteine, related to myocardial infarction (MI) risk. This study aimed, for the first time, to investigate the associations of the polymorphisms CTH G1208T, MTHFR C677T, and A1298C with the prospective risk of developing a fatal or non-fatal first MI.

Methods: This case-referent study included 545 cases later developing a first-ever MI and 1,054 referents from the Northern Sweden Health and Disease Study. Fatal MI was defined as death within 28 days after MI symptoms.

Results: Women, but not men, had a positive association between fatal MI and the CTH G1208T, odds ratio [95% confidence interval] 3.14 [1.16-8.54] for heterozygotes, and the dominant model 3.22 [1.22-8.51], and for the MTHFR A1298C heterozygotes 3.24 [1.26-8.34] and the dominant model 2.63 [1.06-6.50]. The MTHFR C677T polymorphism was not related to MI.

Conclusions: This study indicates that the minor alleles of CTH G1208T and MTHFR A1298C polymorphisms are associated with a higher risk for a fatal MI among women but not for non-fatal MI. No association was found in men.

目的:半胱硫氨酸- γ -裂解酶(CSE)在转硫途径中产生硫化氢(H2S),可能调节心血管功能。CTH基因rs1021737的G1208T多态性,除MTHFR外,已被发现增加同型半胱氨酸,与心肌梗死(MI)风险相关。本研究旨在首次探讨CTH G1208T、MTHFR C677T和A1298C多态性与致死性或非致死性首次心肌梗死的前瞻性风险之间的关系。方法:本研究纳入了来自瑞典北部健康与疾病研究的545例首次心肌梗死病例和1054例参照物。致死性心肌梗死定义为心肌梗死症状出现后28天内死亡。结果:致死性心肌梗死与CTH G1208T呈正相关,女性,而非男性,杂合子的比值比为3.14[1.16-8.54],优势模型为3.22 [1.22-8.51],MTHFR A1298C杂合子的比值比为3.24[1.26-8.34],优势模型为2.63[1.06-6.50]。结论:本研究表明,CTH G1208T和MTHFR A1298C多态性的次要等位基因与女性致死性心肌梗死的高风险相关,而与非致死性心肌梗死无关。在男性中未发现相关。
{"title":"<i>CTH</i> G1208T and <i>MTHFR</i> A1298C polymorphisms are associated with a higher risk of a first myocardial infarction with fatal outcome among women.","authors":"Elisabet Söderström,&nbsp;Jonas Andersson,&nbsp;Stefan Söderberg,&nbsp;Bethany van Guelpen,&nbsp;Torbjörn K Nilsson,&nbsp;Johan Hultdin","doi":"10.1515/dmpt-2022-0119","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0119","url":null,"abstract":"<p><strong>Objectives: </strong>Cystathionine-gamma-lyase (CSE) in the transsulfuration pathway generates hydrogen sulfide (H<sub>2</sub>S), suggested regulating cardiovascular function. The G1208T polymorphism in the <i>CTH</i> gene, rs1021737, has, in addition to <i>MTHFR</i>, been found to increase homocysteine, related to myocardial infarction (MI) risk. This study aimed, for the first time, to investigate the associations of the polymorphisms <i>CTH</i> G1208T, <i>MTHFR</i> C677T, and A1298C with the prospective risk of developing a fatal or non-fatal first MI.</p><p><strong>Methods: </strong>This case-referent study included 545 cases later developing a first-ever MI and 1,054 referents from the Northern Sweden Health and Disease Study. Fatal MI was defined as death within 28 days after MI symptoms.</p><p><strong>Results: </strong>Women, but not men, had a positive association between fatal MI and the <i>CTH</i> G1208T, odds ratio [95% confidence interval] 3.14 [1.16-8.54] for heterozygotes, and the dominant model 3.22 [1.22-8.51], and for the <i>MTHFR</i> A1298C heterozygotes 3.24 [1.26-8.34] and the dominant model 2.63 [1.06-6.50]. The <i>MTHFR</i> C677T polymorphism was not related to MI.</p><p><strong>Conclusions: </strong>This study indicates that the minor alleles of <i>CTH</i> G1208T and <i>MTHFR</i> A1298C polymorphisms are associated with a higher risk for a fatal MI among women but not for non-fatal MI. No association was found in men.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 1","pages":"57-63"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9166916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Therapeutic drug monitoring of teriflunomide: do plasma concentrations predict response to leflunomide in patients with rheumatoid arthritis? 替氟米特的治疗药物监测:血浆浓度是否能预测类风湿关节炎患者对来氟米特的反应?
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-03-01 DOI: 10.1515/dmpt-2021-0236
Tekaya Rawdha, Ben Tekaya Aicha, Ben Ammar Lobna, Salouaje Issam, Ben Sassi Mouna, Saidane Olfa, Bouden Selma, Ben Brahim Takoua, Ben Abdelghani Kawther, Metoui Leila, Sahli Hana, Mahmoud Ines, Abdelmoula Leila

Objectives: Leflunomide is a commonly used treatment for rheumatoid arthritis. It acts by inhibiting dihydroorotate dehydrogenase through its active metabolite teriflunomide. The objective of the study was to investigate the relation between plasma-concentration of teriflunomide and disease-activity in rheumatoid arthritis.

Methods: Data were collected from patients with rheumatoid arthritis on a stable leflunomide dose for at least 2 months. Socio-demographic data, disease characteristics and DAS28 score were recorded. Blood samples were taken for determination of teriflunomide concentration.

Results: A total of 32 serum concentration-time measurements were collected. The concentration of teriflunomide was positively correlated with disease duration of RA (r2=0.2264) and the number of swollen joints (r2=0.2413). There was a trend towards a positive correlation between Health Assessment Questionnaire (HAQ) and plasma teriflunomide concentration (r2=0.1699). Weight was negatively correlated with the residual plasma concentration of teriflunomide (r2=0.2483). However, there was no significant correlation between residual-plasma-concentration of teriflunomide and the following parameters: age, sex, number of tender painful joints, patient-global-assessment, C-reactive protein (CRP) and duration of prescription of leflunomide. We did not find association between disease-activity and residual-plasma-concentration of teriflunomide (r2=0.0021) and haven't been able to define the threshold value of residual-plasma-concentration of leflunomide predictive of a good-response.

Conclusions: We did not find a concentration-effect-relationship. However, therapeutic drug monitoring of teriflunomide may be useful to ensure adherence and evaluate toxic-levels in case of adverse-events.

目的:来氟米特是一种常用的治疗类风湿性关节炎的药物。它通过其活性代谢物特立氟米特抑制二氢乙酸脱氢酶起作用。本研究的目的是探讨类风湿关节炎患者特立氟米特血药浓度与疾病活动度的关系。方法:收集使用稳定来氟米特剂量至少2个月的类风湿关节炎患者的数据。记录社会人口学资料、疾病特征和DAS28评分。取血测定特立氟米特浓度。结果:共采集32项血清浓度-时间测定。特立氟米特浓度与RA病程(r2=0.2264)、肿胀关节数(r2=0.2413)呈正相关。健康评估问卷(HAQ)与特立氟米特血药浓度呈正相关(r2=0.1699)。体重与特立氟米特血浆残留浓度呈负相关(r2=0.2483)。然而,特氟米特血浆残留浓度与以下参数:年龄、性别、压痛关节数量、患者总体评估、c反应蛋白(CRP)和来氟米特处方时间无显著相关性。我们没有发现疾病活动性与特氟米特血浆残留浓度之间的关联(r2=0.0021),也无法确定来氟米特血浆残留浓度预测良好反应的阈值。结论:我们没有发现浓度-效应关系。然而,对特立氟米特的治疗药物监测可能有助于确保依从性,并在发生不良事件时评估毒性水平。
{"title":"Therapeutic drug monitoring of teriflunomide: do plasma concentrations predict response to leflunomide in patients with rheumatoid arthritis?","authors":"Tekaya Rawdha,&nbsp;Ben Tekaya Aicha,&nbsp;Ben Ammar Lobna,&nbsp;Salouaje Issam,&nbsp;Ben Sassi Mouna,&nbsp;Saidane Olfa,&nbsp;Bouden Selma,&nbsp;Ben Brahim Takoua,&nbsp;Ben Abdelghani Kawther,&nbsp;Metoui Leila,&nbsp;Sahli Hana,&nbsp;Mahmoud Ines,&nbsp;Abdelmoula Leila","doi":"10.1515/dmpt-2021-0236","DOIUrl":"https://doi.org/10.1515/dmpt-2021-0236","url":null,"abstract":"<p><strong>Objectives: </strong>Leflunomide is a commonly used treatment for rheumatoid arthritis. It acts by inhibiting dihydroorotate dehydrogenase through its active metabolite teriflunomide. The objective of the study was to investigate the relation between plasma-concentration of teriflunomide and disease-activity in rheumatoid arthritis.</p><p><strong>Methods: </strong>Data were collected from patients with rheumatoid arthritis on a stable leflunomide dose for at least 2 months. Socio-demographic data, disease characteristics and DAS28 score were recorded. Blood samples were taken for determination of teriflunomide concentration.</p><p><strong>Results: </strong>A total of 32 serum concentration-time measurements were collected. The concentration of teriflunomide was positively correlated with disease duration of RA (r<sup>2</sup>=0.2264) and the number of swollen joints (r<sup>2</sup>=0.2413). There was a trend towards a positive correlation between Health Assessment Questionnaire (HAQ) and plasma teriflunomide concentration (r<sup>2</sup>=0.1699). Weight was negatively correlated with the residual plasma concentration of teriflunomide (r<sup>2</sup>=0.2483). However, there was no significant correlation between residual-plasma-concentration of teriflunomide and the following parameters: age, sex, number of tender painful joints, patient-global-assessment, C-reactive protein (CRP) and duration of prescription of leflunomide. We did not find association between disease-activity and residual-plasma-concentration of teriflunomide (r<sup>2</sup>=0.0021) and haven't been able to define the threshold value of residual-plasma-concentration of leflunomide predictive of a good-response.</p><p><strong>Conclusions: </strong>We did not find a concentration-effect-relationship. However, therapeutic drug monitoring of teriflunomide may be useful to ensure adherence and evaluate toxic-levels in case of adverse-events.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 1","pages":"79-85"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9166895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Phytochemical investigation, antioxidant and anticancer activities of various Unani drugs. 植物化学研究、抗氧化和抗癌活性。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-03-01 DOI: 10.1515/dmpt-2022-0110
Mohd Nazir Mannan, Lahari Kuna, Alokananda Chakraborty, Mohammad Zakir, Syeda Hajra Fatima, Ahmed Minhajuddin, Munawwar Husain Kazmi, Tasleem Ahmad

Objectives: To analyze the phytochemicals, antioxidant, and anticancer activities on MCF-7 human breast cancer cell line using aqueous, hydro-ethanol, and methanol extracts of different Unani drugs, e.g., Halela Siyah, Aftimoon, Bisfayej, Ustukhudoos, and Kutki.

Methods: The qualitative examination (alkaloids, terpenoids, tannins, and saponins), anticancer activity, and an antioxidant assay of the three different extracts were done by MTT assay and DPPH assay, respectively, using different Unani drugs.

Results: The qualitative examination confirmed the substantive presence of phytochemical constituents in all the extracts of these drugs. The Methanolic extract of Halela Siyah had the highest DPPH scavenging activity (91%), while Bisfayej had the lowest (58%). Similarly, the hydro-ethanolic extract showed approximately identical activity for Halela Siyah (89%), Aftimoon (88%), Bisfayej (84%), Kutki (82%), and Ustukhudoos (81%). The aqueous extracts of Halela Siyah (88%) had the highest DPPH scavenging activity, whereas Bisfayej (73%) had the lowest. The methanolic extract of Aftimoon demonstrated the greatest anticancer activity (IC50 - 108), while Aftimoon showed the least activity (IC50 - 316). Halela Siyah (IC50 - 175) and Aftimoon (IC50 - 178) showed substantially the same activity in aqueous extracts. Ustukhudoos hydro-ethanol extracts had the highest (IC50 - 130) activity, whereas Aftimoon had the lowest (IC50 - 204).

Conclusions: In conclusion, our findings evaluated the presence of phytochemicals, good antioxidant activity, and anticancer activity in different extracts of drugs used in this study. The study shows these drugs have potential anticancer activity against breast cancer in MCF-7 cell lines.

目的:分析不同乌拉尼药物(Halela Siyah, Aftimoon, Bisfayej, Ustukhudoos, Kutki)的水、水乙醇和甲醇提取物对MCF-7人乳腺癌细胞株的植物化学成分、抗氧化和抗癌活性。方法:采用MTT法和DPPH法分别对三种不同提取物进行定性分析(生物碱、萜类、单宁、皂苷)、抗肿瘤活性和抗氧化活性测定。结果:定性分析证实,这些药物提取物中均含有大量植物化学成分。甲醇提取物对DPPH的清除活性最高(91%),而Bisfayej最低(58%)。同样,水乙醇提取物对Halela Siyah(89%)、Aftimoon(88%)、Bisfayej(84%)、Kutki(82%)和Ustukhudoos(81%)的活性大致相同。水提物对DPPH的清除活性最高(88%),而Bisfayej的清除活性最低(73%)。Aftimoon甲醇提取物的抗癌活性最高(IC50 ~ 108), Aftimoon活性最低(IC50 ~ 316)。Halela Siyah (IC50 - 175)和Aftimoon (IC50 - 178)在水提液中的活性基本相同。水乙醇提取物的活性最高(IC50 ~ 130), Aftimoon最低(IC50 ~ 204)。结论:总之,我们的研究结果评估了本研究中使用的药物的不同提取物中存在的植物化学物质,良好的抗氧化活性和抗癌活性。研究表明,这些药物对MCF-7细胞系的乳腺癌具有潜在的抗癌活性。
{"title":"Phytochemical investigation, antioxidant and anticancer activities of various Unani drugs.","authors":"Mohd Nazir Mannan,&nbsp;Lahari Kuna,&nbsp;Alokananda Chakraborty,&nbsp;Mohammad Zakir,&nbsp;Syeda Hajra Fatima,&nbsp;Ahmed Minhajuddin,&nbsp;Munawwar Husain Kazmi,&nbsp;Tasleem Ahmad","doi":"10.1515/dmpt-2022-0110","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0110","url":null,"abstract":"<p><strong>Objectives: </strong>To analyze the phytochemicals, antioxidant, and anticancer activities on MCF-7 human breast cancer cell line using aqueous, hydro-ethanol, and methanol extracts of different Unani drugs, e.g., Halela Siyah, Aftimoon, Bisfayej, Ustukhudoos, and Kutki.</p><p><strong>Methods: </strong>The qualitative examination (alkaloids, terpenoids, tannins, and saponins), anticancer activity, and an antioxidant assay of the three different extracts were done by MTT assay and DPPH assay, respectively, using different Unani drugs.</p><p><strong>Results: </strong>The qualitative examination confirmed the substantive presence of phytochemical constituents in all the extracts of these drugs. The Methanolic extract of Halela Siyah had the highest DPPH scavenging activity (91%), while Bisfayej had the lowest (58%). Similarly, the hydro-ethanolic extract showed approximately identical activity for Halela Siyah (89%), Aftimoon (88%), Bisfayej (84%), Kutki (82%), and Ustukhudoos (81%). The aqueous extracts of Halela Siyah (88%) had the highest DPPH scavenging activity, whereas Bisfayej (73%) had the lowest. The methanolic extract of Aftimoon demonstrated the greatest anticancer activity (IC<sub>50</sub> - 108), while Aftimoon showed the least activity (IC<sub>50</sub> - 316). Halela Siyah (IC<sub>50</sub> - 175) and Aftimoon (IC<sub>50</sub> - 178) showed substantially the same activity in aqueous extracts. Ustukhudoos hydro-ethanol extracts had the highest (IC<sub>50</sub> - 130) activity, whereas Aftimoon had the lowest (IC<sub>50</sub> - 204).</p><p><strong>Conclusions: </strong>In conclusion, our findings evaluated the presence of phytochemicals, good antioxidant activity, and anticancer activity in different extracts of drugs used in this study. The study shows these drugs have potential anticancer activity against breast cancer in MCF-7 cell lines.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 1","pages":"107-112"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9177359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A metabolic blueprint of COVID-19 and long-term vaccine efficacy. COVID-19代谢蓝图与疫苗长期疗效
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-03-01 DOI: 10.1515/dmpt-2022-0148
Engin Berber, Deepak Sumbria, Serkan Kokkaya

Viruses are obligatory protein-coated units and often utilize the metabolic functions of the cells they infect. Viruses hijack cellular metabolic functions and cause consequences that can range from minor to devastating, as we have all witnessed during the COVID-19 pandemic. For understanding the virus-driven pathogenesis and its implications on the host, the cellular metabolism needs to be elucidated. How SARS-CoV-2 triggers metabolic functions and rewires the metabolism remains unidentified but the implications of the metabolic patterns are under investigation by several researchers. In this review, we have described the SARS-CoV-2-mediated metabolic alterations from in vitro studies to metabolic changes reported in victims of COVID-19. We have also discussed potential therapeutic targets to diminish the viral infection and suppress the inflammatory response, with respect to evidenced studies based on COVID-19 research. Finally, we aimed to explain how we could extend vaccine-induced immunity in people by targeting the immunometabolism.

病毒是必需的蛋白质包被单位,经常利用它们感染的细胞的代谢功能。病毒劫持细胞代谢功能,造成从轻微到毁灭性的后果,正如我们在COVID-19大流行期间所目睹的那样。为了了解病毒驱动的发病机制及其对宿主的影响,需要阐明细胞代谢。SARS-CoV-2如何触发代谢功能并重新连接代谢仍未确定,但几位研究人员正在调查代谢模式的影响。在这篇综述中,我们描述了sars - cov -2介导的代谢改变,从体外研究到COVID-19患者报告的代谢变化。我们还讨论了基于COVID-19研究的证据性研究的潜在治疗靶点,以减少病毒感染和抑制炎症反应。最后,我们的目的是解释我们如何通过针对免疫代谢来延长疫苗诱导的免疫。
{"title":"A metabolic blueprint of COVID-19 and long-term vaccine efficacy.","authors":"Engin Berber,&nbsp;Deepak Sumbria,&nbsp;Serkan Kokkaya","doi":"10.1515/dmpt-2022-0148","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0148","url":null,"abstract":"<p><p>Viruses are obligatory protein-coated units and often utilize the metabolic functions of the cells they infect. Viruses hijack cellular metabolic functions and cause consequences that can range from minor to devastating, as we have all witnessed during the COVID-19 pandemic. For understanding the virus-driven pathogenesis and its implications on the host, the cellular metabolism needs to be elucidated. How SARS-CoV-2 triggers metabolic functions and rewires the metabolism remains unidentified but the implications of the metabolic patterns are under investigation by several researchers. In this review, we have described the SARS-CoV-2-mediated metabolic alterations from <i>in vitro</i> studies to metabolic changes reported in victims of COVID-19. We have also discussed potential therapeutic targets to diminish the viral infection and suppress the inflammatory response, with respect to evidenced studies based on COVID-19 research. Finally, we aimed to explain how we could extend vaccine-induced immunity in people by targeting the immunometabolism.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 1","pages":"15-29"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9177360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
News in DMPT: Leaders in Pharmacogenetics Section. 新闻在DMPT:领导药物遗传学部分。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-03-01 DOI: 10.1515/dmpt-2023-0004
Ingrid Fricke-Galindo, Adrián LLerena
{"title":"News in DMPT: Leaders in Pharmacogenetics Section.","authors":"Ingrid Fricke-Galindo,&nbsp;Adrián LLerena","doi":"10.1515/dmpt-2023-0004","DOIUrl":"https://doi.org/10.1515/dmpt-2023-0004","url":null,"abstract":"","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9178347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Drug metabolism and personalized therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1